Maintenance Guide · Updated November 2026

GLP-1 Exit Strategy: How to Keep Weight Off After Stopping Ozempic or Mounjaro

The STEP 1 extension found that one year after stopping semaglutide and the trial's lifestyle program, participants had regained two-thirds of their prior weight loss. That single data point should change how every GLP-1 patient thinks about their long-term plan. You need an exit strategy before you stop, not after.

I am seven months into Mounjaro at 181.6 lbs and 21.9% body fat. I have not stopped yet. But I think about it constantly, because everything I have read tells me that stopping without a plan is one of the fastest ways to undo months of progress. The weight regain data from clinical trials is not subtle. It is alarming. And pretending it does not apply to me would be naive.

This guide is what I am building for myself: a concrete plan for eventually stepping off GLP-1 medication while keeping the weight off. Whether you are on Ozempic, Wegovy, Mounjaro, or Zepbound, the biology works the same way. The question is whether you can stack enough habits and safeguards to beat the statistics.

What the Clinical Data Actually Shows About Weight Regain

The numbers are hard to ignore. Two major trials tracked what happens after patients stop GLP-1 medications, and both tell a similar story.

STEP 1 Extension (semaglutide/Wegovy): In the off-treatment extension, 327 participants had lost an average of 17.3% of body weight on semaglutide 2.4 mg over 68 weeks. Both the drug and the lifestyle intervention then stopped. By week 120 they had regained 11.6 percentage points, leaving a net loss of 5.6%. That is about two-thirds of the loss. Most cardiometabolic improvements also moved back toward baseline.

SURMOUNT-4 (tirzepatide/Zepbound): In SURMOUNT-4, 670 adults who lost an average of 20.9% on tirzepatide during a 36-week lead-in were randomized to keep taking it or switch to placebo. Over the next 52 weeks, the placebo group’s weight rose 14.0%, while the tirzepatide group’s fell another 5.5%. Only 16.6% of the placebo group kept at least 80% of their earlier loss, versus 89.5% on tirzepatide.

Here is the pattern in table form:

The takeaway is not that GLP-1s do not work. They work extremely well. The takeaway is that for most people, these drugs are managing a chronic condition (obesity), not curing it. The STEP 1 extension authors wrote that their findings “suggest ongoing treatment is required to maintain improvements in weight and health.” Stopping the medication without replacing what it was doing for you is a bit like stopping blood pressure medication and expecting your numbers to stay normal.

Why Weight Regain Happens: The Biology You Cannot Ignore

Understanding why weight comes back helps you plan for it. Researchers generally point to a few overlapping factors. These are simplified explanations, not a full account of the science.

Appetite returns. While you are on semaglutide or tirzepatide, the drug is activating your GLP-1 receptors (and GIP receptors in tirzepatide’s case). Your brain receives strong satiety signals. Food noise quiets down. When you stop, that extra signal goes away and the appetite suppression that made eating less feel easier fades.

Metabolic adaptation. Your body responds to significant weight loss by lowering its resting metabolic rate. A person who weighs 180 lbs after losing 40 lbs burns fewer calories at rest than someone who has always weighed 180 lbs. This adaptation happens with weight loss from any method, and it works against keeping weight off.

Hormonal recalibration takes time. Leptin (the satiety hormone produced by fat cells) drops as you lose fat. Lower leptin signals your brain that energy stores are depleted, which drives increased hunger and decreased energy expenditure. GLP-1 medications override this signal while you are taking them. When you stop, the low leptin levels hit your appetite regulation system without a buffer.

Together, these factors mean that willpower alone is often not enough. You are fighting your own biology. The question is what tools and habits you can put in place to shift the odds in your favor.

Lower Doses and “Microdosing”: What the Labels Actually Say

One of the most discussed ideas in the GLP-1 community is stepping down to a low “maintenance” dose instead of stopping. Before you consider it, know what the FDA labels say, because some online advice doesn’t match them.

• Zepbound and Mounjaro (tirzepatide): The Zepbound label lists maintenance doses of 5 mg, 10 mg or 15 mg weekly. It says the 2.5 mg dose is for starting treatment and is not intended for chronic weight management. If a patient doesn’t tolerate a maintenance dose, the label says the prescriber can consider a lower maintenance dose.
• Wegovy (semaglutide): The Wegovy label lists a maintenance dose of 2.4 mg (recommended) or 1.7 mg weekly for weight reduction and cardiovascular risk reduction.

Doses below these, sometimes called “microdosing,” have not been tested in the trials that support these labels. Compounded “low-dose” products are not FDA-approved, and FDA says compounded GLP-1s should only be used when an approved drug can’t meet a patient’s medical need. Do not lower, skip or stretch doses on your own. Any change to your dose should come from your prescriber.

Practical considerations if you raise this with your prescriber:

• Ask whether a lower labeled maintenance dose makes sense for you, and how you’ll judge whether it’s working.
• Ask how your insurance handles a dose change, since coverage rules vary by plan.
• Ask what to watch for, and how restarting would work if your weight climbs.

These medicines carry a boxed warning about thyroid C-cell tumors and should not be used by people with a personal or family history of medullary thyroid carcinoma or MEN 2. The labels also cover pancreatitis, gallbladder disease, kidney problems from dehydration and use in pregnancy. Review these with your prescriber whenever your dose changes.

If you are exploring options, our provider directory can help you find prescribers.

Building Habits While ON the Medication (This Is the Actual Exit Strategy)

Here is the part most people miss. The best time to build your post-medication habits is right now, while you still have the appetite suppression helping you. The medication gives you a window where making good choices feels easier. Use that window to wire in behaviors that will persist after the drug is gone.

I think of it this way: Mounjaro bought me time. It reduced the noise long enough for me to actually build a training routine, figure out my protein targets, fix my sleep, and learn what hunger versus craving feels like. If I had just coasted on the appetite suppression without building those habits, I would have nothing to fall back on.

The goal is to make the medication redundant, not to depend on it forever.

The 4 Pillars for a Successful Exit

These are the four areas that, based on the research and my own experience, give you the best chance of maintaining weight loss after stopping GLP-1 medication. None of them are optional. They work together.

Pillar 1: Protein Intake

Protein matters for weight maintenance in a few ways:

1. Satiety. Many people find protein-rich meals more filling, which can help once the medication’s appetite effect is gone.
2. Muscle preservation. The 2025 joint nutrition advisory links low protein intake, along with no strength training, to muscle loss during GLP-1 treatment. Our exercise and muscle guide covers this in detail.
3. How much. The advisory notes the adult RDA is 0.8 g per kg per day, says 1.2 to 1.6 g per kg has been proposed during active weight loss, and says prolonged intake at or above 2 g per kg should be avoided. If you have kidney disease, ask your clinician before raising protein.

My target is 160 to 180 grams of protein per day at 181 lbs. That took months to dial in while on Mounjaro because the appetite suppression made eating anything, let alone high-protein meals, feel like a chore. But I forced the habit, and now hitting my protein target is automatic. My number is my own and sits at the high end, so set yours with your clinician rather than copying it.

Pillar 2: Resistance Training (3 Times Per Week)

The 2025 joint advisory recommends regular strength training at least 3 times weekly plus at least 150 minutes of moderate aerobic exercise weekly to help preserve muscle and bone during GLP-1 treatment. Building that routine while you’re still on the medication means it’s already in place if you stop.

You do not need to train like an athlete. Three sessions per week of basic compound lifts (squat, bench, deadlift, rows, overhead press) is a practical way to meet that target. I have been running an upper/lower split three days per week since month two of Mounjaro, and my DEXA scans show I have kept far more lean mass than the trial averages. If you’re curious about supplements like creatine, ask your prescriber first.

Pillar 3: Sleep (7 to 9 Hours, Consistently)

Sleep is the underrated pillar. Short sleep has been linked to obesity risk, and one trial tested what happens when short sleepers get more.

In a 2022 randomized trial in JAMA Internal Medicine, 80 adults with overweight who usually slept less than 6.5 hours got sleep counseling aimed at 8.5 hours in bed. They slept about 1.2 hours more per night and ate about 270 fewer calories a day than the control group, with no diet instructions. It was a small, short trial in younger adults, but it supports treating sleep as part of the plan.

When I am planning my exit from Mounjaro, sleep is the thing I am most focused on protecting. Training and protein I can control through discipline. Sleep requires environmental changes (consistent bedtime, dark room, no screens before bed) that need to be habits before the medication stops.

Pillar 4: Stress Management

Many people eat more, and sleep worse, when they’re under stress. That makes stress worth planning for.

I am not going to prescribe a specific stress management protocol because it is deeply personal. What matters is having one. For me, it is lifting (which doubles as pillar two) and daily walks. For others, it might be meditation, therapy, or restructuring their work schedule. The point is to have a plan for it, because stress can undo good eating and sleep habits.

Setting a “Stop-Loss” Weight: My Personal Rule

I borrowed this concept from my investment banking days. In trading, a stop-loss is a predetermined price at which you sell a position to prevent further losses. You set it before emotions get involved.

I am applying the same logic to weight maintenance. My rule: if I regain 10 lbs above my goal weight, I call my prescriber about restarting GLP-1 medication. No waiting to see if it reverses. No telling myself it is just water weight. No three months of trying harder before admitting the trend is bad.

Here is why this matters. In both the STEP 1 extension and SURMOUNT-4, weight kept rising through the year after the drug stopped. Catching a trend early gives you and your prescriber more options.

Restarting is a prescriber decision. The Wegovy label says that if two or more doses in a row are missed, the prescriber may restart the dose escalation schedule to reduce stomach side effects. Don’t jump back in at your old dose on your own.

Pick your number. Write it down. Agree on it with your prescriber.

Tapering vs. Stopping: What We Know

The trials above tested stopping the drug outright, and that is where the regain numbers come from. Gradual tapering has not been tested with the same rigor, so there is no evidence-based tapering schedule to give you. We removed the schedule this page used to show, because it was based on community discussion rather than clinical guidance.

Questions to work through with your prescriber:

• Is stopping right for me at all? The STEP 1 extension and SURMOUNT-4 both found substantial regain after stopping.
• If we change the dose, what’s the plan? Ask which labeled dose you’d move to, how long you’d stay there, and what result would make you change course.
• How should I track? Many people use regular weigh-ins and a weekly average to see trends rather than daily swings.
• Are my habits ready? Protein, strength training, sleep and stress management are easier to keep up if they’re routine before any change.

What I Am Doing Right Now to Prepare

I have not started tapering yet. I am still on Mounjaro and still losing toward my target of 165 lbs at 13 to 15% body fat. But here is what I am actively doing now to set up my eventual exit:

1. Tracking my protein religiously. 160+ grams per day, every day. The habit needs to be automatic before I stop.
2. Lifting three times per week without exception. I have not missed a session in four months. That consistency needs to be identity-level, not willpower-level.
3. Getting DEXA scans every three months to monitor lean mass. If lean mass drops, I adjust protein or training before it compounds. Read about my latest DEXA results.
4. Sleeping 7.5 to 8 hours consistently. I set an alarm for bedtime, not just wake-up time.
5. Planning the conversation with my prescriber about what happens once I hit my goal weight and hold it for a while.

The medication is the easy part. Building the infrastructure to survive without it is the real work.

The Bottom Line

In the STEP 1 extension, participants regained two-thirds of their weight loss within a year of stopping semaglutide. In SURMOUNT-4, most people switched to placebo regained a large share of their loss. Your best chance of keeping weight off is to build the habits (protein, resistance training, sleep, stress management) while the medication is still helping you, make any dose change with your prescriber using labeled doses, and agree on a clear weight threshold that triggers a call about restarting.

This is not a willpower problem. It is a planning problem. Plan while the medication is still doing the heavy lifting.

FAQ

How much weight do people regain after stopping Ozempic?

In the STEP 1 extension, participants regained about two-thirds of their prior weight loss within one year of stopping semaglutide 2.4 mg and the trial’s lifestyle program. Most cardiometabolic improvements also moved back toward baseline. Individual results vary.

Can I stay on a low dose of Mounjaro for maintenance?

The Zepbound label lists 5 mg, 10 mg and 15 mg as maintenance doses and says 2.5 mg is only for starting treatment. A lower labeled maintenance dose can be considered by your prescriber if you don’t tolerate a higher one. Doses below the labeled range have not been tested in the main trials. Don’t change your dose without your prescriber.

How long should I wait before tapering off my GLP-1?

There is no tested tapering schedule. The main trials studied stopping outright, and both found substantial regain. Talk with your prescriber about whether to change your dose at all, and if so, how to monitor the result.

What is the best exercise to keep weight off after stopping Ozempic?

A 2025 joint nutrition advisory recommends strength training at least 3 times weekly plus at least 150 minutes of moderate aerobic exercise weekly during GLP-1 treatment to help preserve muscle and bone. Keeping that routine after stopping is a sensible way to protect what you’ve built.

Should I keep tracking my weight after stopping GLP-1 medication?

Yes. Regular weigh-ins with a weekly average can help you spot regain early. Agree with your prescriber on a threshold (such as 10 lbs above your goal weight) that triggers a conversation about restarting medication.

Related

Guides:

• Exercise and Muscle on GLP-1s · Creatine on Ozempic and Mounjaro · Fat Loss vs Weight Loss
• DEXA Scan Results on Mounjaro · Mounjaro Dosage Guide · GLP-1 Side Effects
• Mounjaro Weight Loss Plateau · Cheapest GLP-1 Online

Provider Reviews: Ro · Hims · MEDVi · Found · Calibrate

Compare: All Providers · Best GLP-1 Programs · All Guides

What we checked

This AI-assisted public-source desk check reviewed the STEP 1 extension and SURMOUNT-4 trial publications, the FDA prescribing information for Wegovy and Zepbound, the 2025 joint nutrition advisory on GLP-1 therapy and a 2022 sleep-extension trial in JAMA Internal Medicine on November 4, 2026. This is not a clinical review and it is not medical advice. Prices and policies change, so confirm them with the provider or your prescriber before you act.